In separate, live virtual events, Neeraj Agarwal, MD, and Alicia Morgans, MD, MPH, discussed options for a patient with metastatic castration-resistant prostate cancer after multiple lines of therapy.
CASE SUMMARY
Clinical work-up:
Treatment and follow-up:
Thirty-six months later:
“What are you most likely to recommend now that the patient’s disease is progressing, with new liver involvement?”
REFERENCE
1. NCCN. Clinical Practice Guidelines in Oncology. Prostate cancer; version 1.2023. Accessed March 3, 2023. https://bit.ly/41DXvHT
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen